Phase III Study of DA-302168S for Overweight/Obesity Initiated in China
A Phase III clinical trial for DA-302168S has been initiated to evaluate its efficacy and safety in overweight or obese participants.
Company
Pharmaceutical intelligence for DA-302168S with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.